Skip to main content

Alpha-Defensin vs CJC-1295

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Alpha-Defensin

Alpha-defensins are small cationic peptides that are key components of the innate immune system. They have broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses.

Full details →

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Side-by-Side Comparison

AspectAlpha-DefensinCJC-1295
MechanismInsert into microbial membranes to form pores, leading to cell death. Also have immunomodulatory effects including chemotaxis of immune cells and cytokine modulation.CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.
Typical DosageResearch compound - dosing varies by application. Typically studied in laboratory and early clinical research settings rather than for general use.CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.
AdministrationVarious routes studied including topical, local injection, and systemic administration depending on application.Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.
Side EffectsLimited human use data. May cause local inflammation. Potential for immune activation effects.Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.
Best For

Key Differences

Unique to Alpha-Defensin:

Unique to CJC-1295:

Detailed Analysis

Alpha-Defensin and CJC-1295 are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Alpha-Defensin for Recovery & Healing, Immune Support. Choose CJC-1295 for Muscle Growth, Fat Loss, Sleep Quality.

Ready to Learn More?